AbbVie Already Dividend King? Why Apogee Deal Could Cement a Dynasty
AbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Get a concise action plan for financial emergencies, including prioritizing essentials, securing funds, and communicating with creditors promptly.
16,835 articlesAbbVie has quietly built a credible dividend track record since its 2013 spin-off from Abbott. The $10.9B Apogee deal...
Insider moves can signal a lot about a company’s near-term plans and risk. This deep dive looks at Adaptive Biotechno...
You’ve saved diligently and planned for early retirement, only to face the possibility of reduced Social Security ben...
SpaceX is exploring bold ways to run data centers in orbit, powered by solar energy. For NuScale Power investors, the...
SoftBank CEO Masayoshi Son says global AI demand will need roughly $5 trillion each year to scale infrastructure, arg...
With American Express set to report on July 24, analysts say a durable franchise, disciplined capital returns, and a ...
The Fed's Beige Book indicates broad, uneven regional growth through late May and June, with consumer spending up but...
SpaceX is hovering around its $135 IPO price as investors digest post-debut dynamics. One broker, Raymond James, argu...
Insider trades can offer clues about a company’s near-term path. This article digs into a Mineralys insider banked $5...
AMD signals a shift from pure CPUs to AI acceleration, blending edge and cloud compute. This article breaks down what...
CoreWeave is expanding fast on the AI cloud frontier, but heavy borrowing and rising interest expenses are pulling th...
Apple sits near a record price, but its future may still be bright. This guide breaks down the numbers, the moat, and...